KR20250096720A - 대식세포 활성을 조절하기 위한 조성물 및 방법 - Google Patents

대식세포 활성을 조절하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20250096720A
KR20250096720A KR1020257014592A KR20257014592A KR20250096720A KR 20250096720 A KR20250096720 A KR 20250096720A KR 1020257014592 A KR1020257014592 A KR 1020257014592A KR 20257014592 A KR20257014592 A KR 20257014592A KR 20250096720 A KR20250096720 A KR 20250096720A
Authority
KR
South Korea
Prior art keywords
lilrb1
human
lilrb2
binding
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257014592A
Other languages
English (en)
Korean (ko)
Inventor
루카 카세타
스티븐 마이엇
카롤라 리즈
크시슈토프 비. 비헤르
Original Assignee
매코믹스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 매코믹스 리미티드 filed Critical 매코믹스 리미티드
Priority claimed from PCT/GB2023/050592 external-priority patent/WO2023170434A1/en
Publication of KR20250096720A publication Critical patent/KR20250096720A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020257014592A 2022-10-04 2023-03-13 대식세포 활성을 조절하기 위한 조성물 및 방법 Pending KR20250096720A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2214614.6A GB202214614D0 (en) 2022-10-04 2022-10-04 Compositions and methods for modulation of macrophage
GB2214614.6 2022-10-04
PCT/GB2023/050592 WO2023170434A1 (en) 2022-03-11 2023-03-13 Compositions and methods for modulation of macrophage activity

Publications (1)

Publication Number Publication Date
KR20250096720A true KR20250096720A (ko) 2025-06-27

Family

ID=84000149

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020257014592A Pending KR20250096720A (ko) 2022-10-04 2023-03-13 대식세포 활성을 조절하기 위한 조성물 및 방법

Country Status (8)

Country Link
JP (1) JP2025535192A (enExample)
KR (1) KR20250096720A (enExample)
CN (1) CN120435496A (enExample)
AU (1) AU2023232991A1 (enExample)
CR (1) CR20250172A (enExample)
GB (1) GB202214614D0 (enExample)
IL (1) IL319958A (enExample)
MX (1) MX2025003929A (enExample)

Also Published As

Publication number Publication date
JP2025535192A (ja) 2025-10-22
MX2025003929A (es) 2025-05-02
CR20250172A (es) 2025-09-04
IL319958A (en) 2025-05-01
AU2023232991A1 (en) 2025-04-10
CN120435496A (zh) 2025-08-05
GB202214614D0 (en) 2022-11-16

Similar Documents

Publication Publication Date Title
US12209128B2 (en) Anti-PD-L1 antibodies
KR102926972B1 (ko) Pd-l1 및 cd137에 결합하는 항체 분자
CN112218891B (zh) 抗-cd25抗体剂
JP7596447B2 (ja) Ｃｄ３８調節抗体
JP2022161997A (ja) 新規抗ｐｄ－１抗体
JP2021525082A (ja) 抗ｓｉｒｐａ抗体およびその使用法
US20190330351A1 (en) Anti-pd-l1 antibodies
US20160200815A1 (en) Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
US20250197491A1 (en) Compositions and methods for modulation of macrophage activity
CN113194994B (zh) 使用抗trem2抗体的方法
JP2021529520A (ja) 抗ｓｉｒｐ−ベータ１抗体及びその使用方法
JP2021524478A (ja) 抗体分子
JP7299873B2 (ja) Ｃｄ３８抗体
TW202319397A (zh) NKp46結合多肽及其用途
TW202328171A (zh) 靶向NKp46之經修飾之IL-2多肽及其用途
CN114008077A (zh) 抗体和使用方法
AU2015367224A1 (en) IL-21 antibodies
KR20240039025A (ko) 인간 인터류킨-4 수용체 알파 항체
KR20250096720A (ko) 대식세포 활성을 조절하기 위한 조성물 및 방법
US20240376205A1 (en) Targeted interferon alpha fusion proteins and methods of use
WO2025113640A1 (zh) 结合lilrb1/2或pd1-lilrb1/2的抗体及其用途
RU2777573C2 (ru) Антитела против 4-1bb человека и их применение
TW202413412A (zh) 在組合療法中能夠結合到ｃｄ２７之結合劑
CN118434768A (zh) 激动性ltbr抗体以及包含它们的双特异性抗体
HK40038005B (zh) 用於肿瘤特异性细胞清除的抗-cd25

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20250430

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application